Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspective
- 25 February 2013
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 60 (9) , 1528-1533
Abstract
Background Anthracycline agents are used for treatment of acute myeloid leukemia (AML) but may cause late‐onset cardiomyopathy. Current frontline therapy for AML in North America, as reflected in the approach of the Children's Oncology Group (COG) and other pediatric consortia, is adapted from the anthracyline‐intensive Medical Research Council (MRC) regimen. The purpose of this study was to describe early post‐treatment cardiac function as a potential indicator of acute and long‐term risk associated with this approach. Procedure A multi‐center retrospective cohort analysis was conducted of AML survivors diagnosed from 2004 to 2009 and treated with MRC‐based regimens. Change in left ventricular shortening fraction (LVSF) on echocardiogram was determined from baseline to latest post‐treatment/pre‐relapse value; associations with potential predictors were examined. Results This cohort of pediatric survivors (n = 52) was assessed at a median interval of 13 months from end of treatment. Mean cumulative anthracycline dose was 339 ± 14 mg/m2. Mean baseline and post‐treatment LVSF were 39.3 ± 0.8% and 35.4 ± 0.9%, respectively; mean percent change for individuals was −8.4 ± 2.8% (P < 0.001). Cardiac‐directed medications were initiated in four patients (7.7%). Decline in LVSF was significantly associated with cumulative anthracycline dose, increasing BMI and Hispanic ethnicity. Conclusion Early, significant decline in LVSF was observed following treatment with these MRC‐based regimens. Elevated BMI and Hispanic ethnicity were identified as new independent risk factors. Children and adolescents so treated are at substantial risk for late‐onset cardiomyopathy, require monitoring with annual echocardiogram per current COG survivorship guidelines, and are good candidates for appropriate cardioprotection strategies. Pediatr Blood Cancer 2013;160:1528–1533.Keywords
This publication has 38 references indexed in Scilit:
- Systolic and diastolic dysfunction in long-term adult survivors of childhood cancerEuropean Journal of Cancer, 2011
- Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First CenturyJournal of Clinical Oncology, 2010
- Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohortBMJ, 2009
- Anthracycline Dose Intensification in Acute Myeloid LeukemiaNew England Journal of Medicine, 2009
- Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990–2004JNCI: Journal of the National Cancer Institute, 2008
- Anthracycline cardiotoxicity in long-term survivors of childhood cancerCardiovascular Toxicology, 2007
- Pathogenesis of Cardiotoxicity Induced by AnthracyclinesSeminars in Oncology, 2006
- Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trialsLeukemia, 2005
- Pathophysiology of anthracycline‐ and radiation‐associated cardiomyopathies: Implications for screening and preventionPediatric Blood & Cancer, 2005
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004